Dare Bioscience, Inc. Business Combination, Consideration Transferred
Dare Bioscience, Inc. (DARE) reported Business Combination, Consideration Transferred of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-30.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2021-03-30
- Dare Bioscience, Inc. business combination, consideration transferred for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Dare Bioscience, Inc. business combination, consideration transferred for fiscal 2019 was $2.37M.
- Dare Bioscience, Inc. business combination, consideration transferred for fiscal 2018 was $0.00.
| Period end | Business Combination, Consideration Transferred 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-30 |
| 2019-12-31 | $2.37M 10-K · filed 2021-03-30 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |